« MinervaX announces positive data from Phase I clinical trial | Main | Primary Endpoint Data from Phase I Part B »
Monday
Sep192016

Innovation Foundation Grant

MinervaX announces that the company has been awarded a grant worth DKK 4.1 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for the development of its Group B Streptococcal Vaccine.